Precigen (PGEN) Change in Account Payables (2012 - 2026)
Precigen (PGEN) reported Change in Account Payables of -$9.5 million for Q1 2026, down 8030.77% year-over-year from $119950.5 in Q1 2025, and down 245.55% quarter-over-quarter from $6.5 million in Q4 2025.
Precigen (PGEN) Change in Account Payables (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Change in Account Payables data on file, last reported at -$9.5 million in Q1 2026.
- Change in Account Payables for Q1 2026 came in at -$9.5 million, down 8030.77% year-over-year; the trailing twelve-month figure through Mar 2026 was -$628000.0 (up 48.57% YoY), and the FY2025 annual result was $8.8 million, up 466.04% from the prior year.
- Change in Account Payables retreated to -$9.5 million in Q1 2026 per PGEN's latest filing, from $6.5 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $6.5 million in Q4 2025 and troughed at -$9.5 million in Q1 2026.
- A 5-year average of -$72823.5 and a median of -$249000.0 in 2023 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2024 and 2026: Change in Account Payables soared 1165.46% in 2024, then sank 8030.77% in 2026.
- A 5-year view of Change in Account Payables shows it stood at -$349000.0 in 2022, then plunged by 89.68% to -$662000.0 in 2023, then fell by 19.03% to -$788000.0 in 2024, then surged by 929.44% to $6.5 million in 2025, then sank by 245.55% to -$9.5 million in 2026.
- Business Quant data shows PGEN's Change in Account Payables at -$9.5 million in Q1 2026, $6.5 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -9.42 Mn |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn | -9.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.51 Mn |
| Mar 31, 2026 | -9.51 Mn |
| Dec 31, 2025 | 6.54 Mn |
| Dec 31, 2025 | 6.54 Mn |
| Sep 30, 2025 | 1.55 Mn |
| Sep 30, 2025 | 1.55 Mn |
| Jun 30, 2025 | 801,000.00 |
| Jun 30, 2025 | 801,000.00 |
| Mar 31, 2025 | -117,000.00 |
| Mar 31, 2025 | -117,000.00 |
| Dec 31, 2024 | -788,000.00 |
| Dec 31, 2024 | -788,000.00 |
| Sep 30, 2024 | -841,000.00 |
| Sep 30, 2024 | -841,000.00 |
| Jun 30, 2024 | 525,000.00 |
| Jun 30, 2024 | 525,000.00 |
| Mar 31, 2024 | 2.65 Mn |
| Mar 31, 2024 | 2.65 Mn |
| Dec 31, 2023 | -662,000.00 |
| Dec 31, 2023 | -662,000.00 |